An FDA program that manages the Drug Development Tool (DDT) qualification process under section 507 of the Federal Food, Drug, and Cosmetic (FD&C) Act. It guides stakeholders in the development and refinement of DDTs (e.g., biomarkers, clinical outcome assessments) determined to aid drug development and regulatory review.
